Monitor for Phase 3 NPC1 trial results in Q3 2026, which could be a more significant catalyst than this patent licensing announcement. The MIT patent strengthens IP but does not guarantee clinical or commercial success.
Price Chart
Executive Summary
Rafael Holdings announced an exclusive patent license from MIT covering the use of cyclodextrins in Alzheimer's patients with the ApoE4 genetic mutation, strengthening its IP for Trappsol® Cyclo™. The filing also notes upcoming Phase 3 results for its Niemann-Pick disease trial in Q3 2026.
Key Facts
- Rafael Holdings subsidiary Cyclo Therapeutics secured an exclusive license from MIT for U.S. Patent No. 12285440
- The patent covers use of cyclodextrins in Alzheimer's patients with the ApoE4 genetic mutation
- ApoE4 is present in 50-70% of Alzheimer's patients and is a key risk factor
- Trappsol® Cyclo™ is in a pivotal Phase 3 trial for Niemann-Pick Disease Type C1 (NPC1)
- Phase 3 results for the Transport NPC study are expected in Q3 2026
Financial Impact
No immediate financial impact disclosed; potential long-term value from IP protection and pipeline advancement
Risk Factors
- Clinical trial results may not meet expectations
- Alzheimer's drug development has high failure rates
- No guarantee the licensed patent will lead to an approved therapy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-046380 |
| Document: ea028725801ex99-1.htm | 0001213900-26-046380 |
| Document: 0001213900-26-046380-index-headers.html | 0001213900-26-046380 |
| Document: 0001213900-26-046380-index.html | 0001213900-26-046380 |
| Document: 0001213900-26-046380.txt | 0001213900-26-046380 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 8-K | $1.32 | awaiting T+20 | — | $1.29 (−2.27%) |
Sep 30, 2026 27d ago | Press Release | $1.32 | awaiting T+20 | — | $1.29 (−2.27%) |
Aug 18, 2026 10w ago | Institutional Cluster | $1.86 $2.10 | ▲ +12.90% | ▲ +13.89% | $1.29 (−30.65%) |
Jun 11, 2026 19w ago | 8-K | $2.12 $2.27 | ▲ +7.08% | ▲ +5.18% | $1.29 (−39.15%) |
Jun 10, 2026 19w ago | 8-K | $1.78 $2.27 | ▲ +27.53% | ▲ +23.91% | $1.29 (−27.53%) |
Jun 10, 2026 19w ago | Press Release | $1.78 $2.27 | ▲ +27.53% | ▲ +23.91% | $1.29 (−27.53%) |
Apr 22, 2026 26w ago | 8-K | $1.30 $1.35 | ▲ +3.85% | ▲ +0.68% | $1.29 (−0.77%) |
Mar 16, 2026 32w ago | Press Release | $1.32 $1.22 | ▼ −7.58% | ▼ −11.88% | $1.29 (−2.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers